PLUS1
0.0711
-0.029 (-28.97%)
-0.029 (-28.97%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 38,050,956 |
|
|||||
| News | (1) | ||||||
| Day High | 0.1005 | Low High |
|||||
| Day Low | 0.091 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ContraFect Corporation | CFRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.029 | -28.97% | 0.0711 | 19:59:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.095 | 0.091 | 0.1005 | 0.0921 | 0.1001 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 14,950 | 38,050,956 | $ 0.0940475 | $ 3,578,597 | - | 0.083 - 4.54 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:55 | formt | 45,120 | $ 0.0711 | USD |
Period:
Draw Mode:
ContraFect Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 3.11M | 43.68M | 43.64M | $ - | $ - | -0.56 | -0.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 3.70% |
ContraFect News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CFRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0907 | 0.1202 | 0.083 | 0.1016278 | 49,905,297 | -0.0196 | -21.61% |
| 1 Month | 0.0942 | 0.1202 | 0.083 | 0.1015205 | 17,697,042 | -0.0231 | -24.52% |
| 3 Months | 0.1751 | 0.197 | 0.083 | 0.1073389 | 6,818,611 | -0.104 | -59.39% |
| 6 Months | 0.3697 | 0.3697 | 0.083 | 0.1428012 | 3,933,127 | -0.2986 | -80.77% |
| 1 Year | 2.37 | 4.54 | 0.083 | 0.2606804 | 2,246,473 | -2.30 | -97.0% |
| 3 Years | 1.07 | 13.25 | 0.083 | 1.45 | 985,058 | -0.9989 | -93.36% |
| 5 Years | 1.16 | 13.25 | 0.083 | 1.26 | 840,466 | -1.09 | -93.87% |
ContraFect Description
| ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis. |